Drug Profile


Alternative Names: LY-2189265; Trulicity

Latest Information Update: 13 Jan 2017

Price : $50

At a glance

  • Originator Eli Lilly
  • Class Antihyperglycaemics; Recombinant fusion proteins
  • Mechanism of Action Glucagon like peptide 1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Type 2 diabetes mellitus

Most Recent Events

  • 01 Dec 2016 Phase-II clinical trials in Type-2 diabetes mellitus (Adjunctive treatment) in USA, Mexico, Czech Republic, Poland, Puerto Rico (SC) (NCT02973100)
  • 01 Dec 2016 Phase-III clinical trials in Type-2 diabetes mellitus (In children, In adolescents) in USA, Brazil, Mexico (SC) (NCT02963766)
  • 22 Nov 2016 Eli Lilly plans a phase II trial for Type-2 diabetes mellitus (Adjunctive treatment) in USA, Mexico, Czech Republic, Poland and Romania (SC) (NCT02973100)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top